Finland’s leading healthcare service provider, Suomen Terveystalo Oy, commonly known as Terveystalo, has recently unveiled the incorporation of Nightingale Health’s groundbreaking blood analysis technology into its routine health assessments for occupational health. This substantial update has already been implemented for Terveystalo’s occupational health clients throughout Finland, marking a significant advancement in the field of healthcare.
Nightingale Health is a distinguished player in the realm of advanced blood analysis, and its partnership with Terveystalo denotes a pivotal development in the medical industry. The two entities have worked closely in recent months to seamlessly integrate Nightingale Health’s disease risk evaluations and diagnostic blood values into the daily operations of Terveystalo’s occupational health professionals and laboratories.
An impressive aspect of this collaboration is the extensive logistical network and result delivery capability that Nightingale Health has established to serve Terveystalo’s locations across Finland, spanning a notable distance of 1,200 kilometers. Despite the vast geographical coverage, Nightingale Health has ensured a rapid turnaround time that aligns with the critical response times required in the healthcare sector.
Terveystalo’s stature as Finland’s largest occupational health service provider cannot be overstated, as it extends its services to over 27,000 companies and other organizations, benefitting approximately 700,000 employees. This solidifies the company’s role in safeguarding the welfare of Finland’s workforce.
With a comprehensive network of more than 370 clinics situated across Finland, Terveystalo is well-equipped to provide top-tier health and well-being services to a diverse range of individuals. The addition of Nightingale Health’s blood biomarker-based risk assessments further enhances the value of Terveystalo’s health checks, enabling the identification of disease risks related to eight common chronic diseases from a single blood sample.
The all-encompassing health assessment now encompasses evaluations for myocardial infarction, cardiovascular disease, type 2 diabetes, liver fibrosis and cirrhosis, chronic kidney disease, COPD, lung cancer, and alcohol liver disease, thus ensuring a comprehensive approach to safeguarding individuals’ health.
The integration of Nightingale Health’s state-of-the-art blood analysis technology into Terveystalo’s routine health checks undoubtedly signifies a paradigm shift in healthcare, indicating a shift towards proactive and preventive measures in managing chronic diseases. This partnership underscores the significance of leveraging innovative technologies to enhance healthcare services, ultimately benefitting individuals and communities on a larger scale.
+ There are no comments
Add yours